◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

SUPERNUS PHARMACEUTICALS, INC.

CIK: 1356576 SIC: 2834
$718.95M
Revenue
$-38.55M
Net Income
89.63%
Gross Margin
-8.66%
Op. Margin
$164.62M
Free Cash Flow
Financial Statements Quarterly (10-Q)
Showing 7 of 39 quarterly reports available
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
+ Total Revenue $211.57M $192.10M $165.45M $149.82M $174.16M $175.69M $168.32M
Revenue Growth % (YoY) 21.5% 9.3% -1.7% nan% nan% nan% nan%
Cost of Revenue $23.01M $18.96M $16.83M $15.76M $26.10M $17.58M $17.92M
+ Gross Profit $188.56M $173.14M $148.63M $134.06M $148.06M $158.11M $150.41M
Gross Margin % 89.1% 90.1% 89.8% 89.5% 85.0% 90.0% 89.4%
Operating Expenses $215.51M $252.33M $153.31M $160.08M $152.75M $134.84M $145.76M
Research & Development $27.83M $29.37M $22.11M $26.93M $28.65M $29.04M $26.18M
Selling General & Admin $122.39M $179.68M $93.55M $89.94M $79.41M $69.75M $85.90M
+ Operating Income $-3.94M $-60.23M $12.14M $-10.26M $21.41M $40.84M $22.57M
Operating Margin % -1.9% -31.4% 7.3% -6.8% 12.3% 23.2% 13.4%
Interest Expense - - - - - - -
Other Income/Expense $2.02M $2.28M $4.53M $4.42M $4.98M $4.10M $3.73M
Income Before Tax $-1.91M $-57.95M $16.67M $-5.83M $26.38M $44.94M $26.30M
Income Tax Expense $2.19M $-12.84M $-5.83M $6.00M $11.05M $6.45M $6.39M
+ Net Income $-4.11M $-45.12M $22.50M $-11.83M $15.33M $38.50M $19.92M
Net Margin % -1.9% -23.5% 13.6% -7.9% 8.8% 21.9% 11.8%
Basic EPS -0.07 -0.80 0.40 -0.21 0.28 0.70 0.36
Diluted EPS -0.07 -0.80 0.40 -0.21 0.27 0.69 0.36
Basic Shares Outstanding - 56.6M 56.0M 55.9M 123K 55.1M 55.0M
Diluted Shares Outstanding - 56.6M 56.6M 55.9M 167K 56.0M 55.7M
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Cash & Cash Equivalents $128.45M $151.37M $144.71M $115.85M $69.33M $31.67M $52.09M
Accounts Receivable $187.80M $171.25M $140.83M $145.64M $142.08M $145.41M $152.49M
Inventory $112.48M - $44.02M $49.42M $54.29M $63.98M $68.16M
Other Current Assets $65.33M $62.08M $31.42M $28.93M $36.09M $27.40M $23.17M
Total Current Assets $644.18M $593.89M $738.87M $687.58M $686.07M $640.00M $591.00M
Property Plant & Equipment $10.53M $10.63M $11.07M $11.34M $11.54M $11.88M $12.27M
Goodwill $124.88M $119.08M $117.02M $117.02M $117.02M $117.02M $117.02M
Intangible Assets $569.46M $623.48M $481.31M $502.13M $521.91M $540.16M $559.64M
Other Non-current Assets $63.80M $62.43M $27.96M $29.22M $31.53M $33.65M $35.89M
Total Assets $1.45B $1.42B $1.38B $1.35B $1.37B $1.34B $1.32B
Accounts Payable $2.68M - - - $4.59M - -
Accrued Liabilities $107.80M - - - $76.35M - -
Other Current Liabilities $38.22M $26.32M $27.70M $4.75M - - $3.62M
Total Current Liabilities $338.17M $330.63M $286.36M $281.77M $292.40M $291.51M $308.66M
Deferred Tax Liabilities - - - $981.00K $4.96M $7.36M $11.44M
Other Non-current Liabilities $22.19M $7.82M $7.76M $7.46M $7.60M $7.35M $7.29M
Total Liabilities $390.93M $370.09M $318.50M $316.58M $332.34M $335.55M $358.38M
Common Stock $57.00K $57.00K $56.00K $56.00K $56.00K $55.00K $55.00K
Retained Earnings $517.88M $521.98M $567.10M $544.60M $556.43M $541.10M $502.60M
Total Stockholders Equity $1.06B $1.05B $1.06B $1.03B $1.04B $1.01B $957.45M
Total Liabilities & Equity $1.45B $1.42B $1.38B $1.35B $1.37B $1.34B $1.32B
Breakdown Q4 2025
(Dec 31, 2025)
Q3 2025
(Sep 30, 2025)
Q2 2025
(Jun 30, 2025)
Q1 2025
(Mar 31, 2025)
Q4 2024
(Dec 31, 2024)
Q3 2024
(Sep 30, 2024)
Q2 2024
(Jun 30, 2024)
Net Income $-4.11M $-45.12M $22.50M $-11.83M $15.33M $38.50M $20.04M
Depreciation & Amortization $25.02M $66.55M $41.74M $20.38M $18.84M $61.57M $41.47M
Stock-based Compensation $9.65M $23.40M $15.57M $8.07M $7.63M $20.12M $12.45M
Deferred Income Tax $19.00M $-13.80M $-11.15M $-3.99M $-72.00K $-20.06M $-13.60M
Change in Receivables $16.42M $5.88M $-1.25M $3.56M $-3.33M $1.25M $8.34M
Change in Inventory $4.18M $3.32M $-9.62M $-4.73M $-3.19M $-12.62M $-8.02M
Operating Cash Flow $19.86M $27.47M $89.13M $30.60M $44.41M $127.55M $74.03M
Capital Expenditure $427.00K $911.00K $782.00K $327.00K $213.00K $512.00K $312.00K
Acquisitions - $293.09M - - - - -
Sales of Investments $39.32M $735.16M $266.61M $156.20M $132.98M $365.89M $217.77M
Investing Cash Flow $-51.31M $55.42M $6.71M $37.32M $-12.64M $-177.23M $-100.22M
Stock Issued $8.56M $29.06M $5.32M $2.04M $6.88M $8.03M $4.57M
Financing Cash Flow $8.53M $604.00K $-20.46M $-21.40M $5.89M $6.30M $3.23M
Net Change in Cash $-22.92M $83.49M $75.38M $46.52M $37.66M $-43.38M $-22.96M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Total Revenue $192.10M - $507.38M -
Cost of Revenue $18.96M - $51.55M -
Operating Expenses $252.33M - $565.73M -
Research & Development $29.37M - $78.41M -
Selling General & Admin $179.68M - $363.17M -
Operating Income $-60.23M - $-58.35M -
Other Income/Expense $2.28M - $11.23M -
Income Before Tax $-57.95M - $-47.12M -
Income Tax Expense $-12.84M - $-12.67M -
Net Income $-45.12M $19.92M $-34.45M -
Basic EPS -0.80 - -0.61 -
Diluted EPS -0.80 - -0.61 -
Basic Shares Outstanding $56.55M - $56.13M -
Diluted Shares Outstanding $56.55M - $56.13M -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $151.37M $69.33M
Accounts Receivable $171.25M $142.08M
Other Current Assets $62.08M $36.09M
Total Current Assets $593.89M $686.07M
Property Plant & Equipment $10.63M $11.54M
Goodwill $119.08M $117.02M
Intangible Assets $623.48M $521.91M
Other Non-current Assets $62.43M $31.53M
Total Assets $1.42B $1.37B
Other Current Liabilities $26.32M -
Total Current Liabilities $330.63M $292.40M
Deferred Tax Liabilities - $4.96M
Other Non-current Liabilities $7.82M $7.60M
Total Liabilities $370.09M $332.34M
Common Stock $57.00K $56.00K
Retained Earnings $521.98M $556.43M
Total Stockholders Equity $1.05B $1.04B
Total Liabilities & Equity $1.42B $1.37B
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-45.12M $19.92M $-34.45M -
Depreciation & Amortization - - $66.55M -
Stock-based Compensation - - $23.40M -
Deferred Income Tax - - $-13.80M -
Change in Receivables - - $5.88M -
Change in Inventory - - $3.32M -
Operating Cash Flow - - $27.47M -
Capital Expenditure - - $911.00K -
Acquisitions - - $293.09M -
Sales of Investments - - $735.16M -
Investing Cash Flow - - $55.42M -
Stock Issued - - $29.06M -
Financing Cash Flow - - $604.00K -
Net Change in Cash - - $83.49M -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-Q filings.

Quarterly data represents single quarter results (Q1-Q4). Some items may show year-to-date values if quarterly breakdown is unavailable.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...